Table 2 Sociodemographic and clinical characteristics: Part A-qualitative interviews
Characteristic | Total (N = 35) |
|---|---|
Age (years) | |
Mean (SD) | 45.1 (15.8) |
Median [Range] | 46.0 [19–74] |
Gender, n (%) | |
Female | 23 (65.7) |
Ethnicity, n (%) | |
Hispanic or Latino | 1 (2.9) |
Not Hispanic or Latino | 34 (97.1) |
Racial backgrounda, n (%) | |
American Indian or Alaska Native | 1 (2.9) |
Asian | 1 (2.9) |
Black or African American | 3 (8.6) |
Native Hawaiian or Other Pacific Islander | 1 (2.9) |
White | 28 (80.0) |
Other: specified “biracial” | 1 (2.9) |
Missing | 1 (2.9) |
Employment status, n (%) | |
Employed, full-time | 17 (48.6) |
Employed, part-time | 5 (14.3) |
Student | 3 (8.6) |
Retired | 5 (14.3) |
Disabled | 4 (11.4) |
Otherb | 2 (5.7) |
Highest level of education, n (%) | |
Secondary/high school | 11 (31.4) |
Some college | 8 (22.9) |
College degree | 13 (37.1) |
Postgraduate degree | 2 (5.7) |
Other: specified “massage therapist”; STNA | 1 (2.9) |
Time since diagnosis (years) | |
Mean (SD) | 11.9 (13.7) |
Median [Range] | 6.8 [0–58] |
Most recent CRP score (mg/L) | |
Mean (SD) | 19.3 (32.7) |
Current treatmenta, n (%) | |
Biologics | |
Adalimumab | 7 (20.0) |
Certolizumab | 3 (8.6) |
Infliximab | 3 (8.6) |
Ustekinumab | 6 (17.1) |
Tofacitinib | 1 (2.9) |
Vedolizumab | 4 (11.4) |
Immunomodulators | |
Azathioprine | 2 (5.7) |
Mercaptopurine | 1 (2.9) |
Corticosteroids | |
Budesonide | 3 (8.6) |
Prednisone | 5 (14.3) |
Oral aminosalicylates | |
Sulfasalazine | 2 (5.7) |
Mesalamine | 8 (22.9) |
Anti-diarrheals | |
Loperamide | 1 (2.9) |
Comorbid conditionsa, n (%) | |
No other conditions | 13 (37.1) |
Allergic rhinitis | 3 (8.6) |
Anemia | 2 (5.7) |
Anxiety | 4 (11.4) |
Arthritis | |
Enteropathic arthritis | 1 (2.9) |
Osteoarthritis | 3 (8.6) |
Rheumatoid arthritis | 1 (2.9) |
Asthma | 3 (8.6) |
Cancerc | 1 (2.9) |
COPD | 1 (2.9) |
Depression | 4 (11.4) |
GERD | 7 (20.0) |
Hypertension | 8 (22.9) |
Multiple sclerosis | 1 (2.9) |
Psoriasis | 1 (2.9) |
Other health conditionsa, d | 9 (26.0) |